CGEM SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWCullinan Therapeutics Announces Positive Clinical Data for Velinotamig in Systemic Lupus Erythematosus at ACR Convergence 2026

Nov 9, 2026

8-K

Cullinan Therapeutics Announces Presentations for CLN-049 and Velinotamig at the 68th ASH Annual Meeting

Nov 4, 2026

8-K

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC Under FDA Real-Time Oncology Re

Oct 1, 2026

8-K

Cullinan Therapeutics Highlights Fourth Quarter 2026 Pipeline Milestones Across Immunology and Oncology T Cell Engager Portfolio

Sep 24, 2026

8-K

Zipalertinib Plus Chemotherapy Demonstrates Positive Progression-Free Survival in REZILIENT3 Phase 3 Trial for First-Line NSCLC

Sep 14, 2026

8-K

Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 REZILIENT3 Trial for First-Line NSCLC

Aug 12, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

Up to 14,421,070 Shares of Common Stock

Jun 4, 2024

424B4

11,900,000 Shares-

Jan 11, 2021

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 16, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 16, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Michaelson Jennifer (Reporting)

Nov 6, 2026

144

Form 144 - Report of proposed sale of securities

Nov 5, 2026

Michaelson Jennifer (Reporting)

Sep 10, 2026

144

Form 144 - Report of proposed sale of securities

Sep 8, 2026

Michaelson Jennifer (Reporting)

Aug 14, 2026

SCHEDULE 13G/A

BIOTECHNOLOGY VALUE FUND L P (Filed by)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 5, 2024

CORRESP

Form CORRESP - Correspondence

May 31, 2024

LETTER

Form UPLOAD - SEC-generated letter

May 20, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

May 19, 2023

CORRESP

Form CORRESP - Correspondence

May 16, 2023

CORRESP

Form CORRESP - Correspondence

Mar 17, 2023

Cullinan Therapeutics, Inc. CGEM · SEC Filings